Survival of patients with MRC adverse-risk cytogenetics according to TP53 mutation status. OS of MRC adverse-risk patients with mutated TP53, compared with patients with wild-type TP53 and complex or noncomplex adverse cytogenetics. A complex karyotype was defined as ≥4 unrelated abnormalities per the MRC classification. P values were calculated from a bivariate Cox proportional hazards model stratified for trial arm, using the Wald test. mut, mutated; wt, wild-type.